The speed at which Next-generation sequencing (NGS) has integrated with other fields of clinical life sciences such as molecular pathology, molecular diagnostics etc., has resulted in dramatic expansion of the depth & breadth of genomic information that is available to oncologists. Different methods in which this rather new technology is currently applied to enhance patient care specifically with solid tumors and hematological malignancies all work towards revenue generation for the NGS market. A focused understanding of the guidelines & practices for assessing the validity and clinical utility of genetic variants identified through experimental NGS oncology testing is imperative in order to fully capitalize on the vast potential offered by the technology.
NGS has exhibited strong potential for the growth of precision medicine and companion diagnostics for obliteration of chronic diseases and enhancement of immunotyping. Using which the drug development segment has been heading towards solutions better equipped to decipher DNA/RNA sequences. This fuels development of more efficient, targeted and complex medicine, & allows genomic/proteomic clinicians &lab administrators in clinics &hospitals to increasingly adopt installation of NG sequencers aimed for applications in in-vitro diagnostics and determination of treatment protocols thus influencing NGS demand.
Furthermore, with the continual reduction in sequencig costs for whole genomes, Whole Genome Sequencing (WGS), including exomes, has provided a deluge of key insights to clinicians regarding the molecular basis of cancer. Key impact on clinical investigation and development due to findings primarily possible due to NGS. For instance, the mechanism of myeloproliferative neoplasms and role of calreticulin in its mutation and other such insights from WGS find important application for clinical development of novel precision therapeutic solutions.
Additionally, further development of WGS is expected to also benefit studies involving structural rearrangement detection (loss of heterozygosity, copy number changes, ploidy, etc.) and heterogeneity estimation and tumor purity for NGS usage in clinical diagnostics. NGS IVD is the next major area of focus for a number of major market entities and players such as Illumina, Roche Sequencing, Qiagen, Pacific Bioscience are all involved in the development and enhancement of their product portfolios to capitalize on the lucrative avenue. Thus, the next generation sequencing is expected to remain highly competitive and dynamic in nature over the coming decade.
To request a sample copy or view summary of this report, click the link below: